Compare FARM & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FARM | GBIO |
|---|---|---|
| Founded | 1912 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 35.4M |
| IPO Year | N/A | 2020 |
| Metric | FARM | GBIO |
|---|---|---|
| Price | $1.52 | $5.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.75 | ★ $10.67 |
| AVG Volume (30 Days) | ★ 77.3K | 52.0K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $338,816,000.00 | $15,270,000.00 |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $3.00 |
| 52 Week High | $3.29 | $13.80 |
| Indicator | FARM | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 48.66 |
| Support Level | $1.49 | $5.14 |
| Resistance Level | $1.62 | $5.38 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 40.00 | 56.00 |
Farmer Bros Co is engaged in manufacturing, wholesaling, and distributing coffee, tea, and culinary products to food-service establishments and retailers in the United States. The company's customers include restaurants, hotels, offices, casinos, convenience stores, healthcare facilities, and other food-service providers. The company's product categories include roast and ground coffee, frozen liquid coffee, flavored and unflavored iced and hot teas, culinary products, spices, and other beverages, such as cappuccino, cocoa, granitas, and ready-to-drink iced coffee.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.